Morgan Stanley raised the firm’s price target on Alphatec (ATEC) to $23 from $21 and keeps an Equal Weight rating on the shares. Going into 2026, MedTech “looks well-positioned on several fronts” as the firm thinks major product cycles and a supportive hospital spending environment, combined with trough valuations, make for “a solid industry setup,” the analyst tells investors in a note for the group on the upcoming year.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATEC:
- Alphatec price target raised to $21 from $16 at Morgan Stanley
- Alphatec Holdings Mourns Loss of Board Member
- Alphatec price target raised to $23 from $22 at Barclays
- Alphatec’s Earnings Call: Strong Growth and Positive Outlook
- Alphatec Holdings: Strong Financial Performance and Strategic Growth Justify Buy Rating